osteoprotegerin


Also found in: Medical, Acronyms, Wikipedia.

osteoprotegerin

[¦äs·tē·prō′teg·ərin]
(biochemistry)
A protein that plays a central role in regulating bone mass.
Mentioned in ?
References in periodicals archive ?
Penninger, "Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development," Immunology and Cell Biology, vol.
Donnet-Hughes, "Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses," American Journal of Physiology.
Radzikowska et al., "High levels of osteoprotegerin and soluble receptor activator of nuclear factor [kappa]B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor a treatment," Arthritis and Rheumatism, vol.
Additionally, the mRNA levels for RUNX2 (an osteoblast-specific transcription factor) and osteoprotegerin (a RANKL antagonist) were elevated by LPNS.
Osteoprotegerin (OPG), receptor activator of nuclear factor-[kappa]B (RANK), and RANK ligand (RANKL), are proteins that regulate osteoclast formation and differentiation (Lacey et al., 1998, Hofbauer, 1999, Teitelbaum, 2000, Feng, 2005, Luo et al., 2006).
Liu et al., "Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases," International Journal of Cancer, vol.
Miyamoto et al., "Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor and osteoprotegerin expression," Journal of Bone and Mineral Research, vol.
Another research indicates that alendronate inhibits artery calcification by upregulating osteopontin and osteoprotegerin expression in rat model [50].
Regarding osteoprotegerin, studies have shown that it stimulates autophagy via important signaling pathways in vascular smooth muscle cells, leading this way to the weakening and remodeling of the arterial wall [31].
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
(20) Recently, it has been found that untreated male SHR show alveolar bone with a high expression of RANKL (receptor activator of nuclear factor kappa-B ligand, a protein involved in osteoclast activation), a high ratio of RANKL/OPG (osteoprotegerin, a decoy receptor for RANKL), a high number of positive tartrate resistant acid phosphatase cells (an enzyme highly expressed by osteoclasts), greater bone loss, and reduced bone density.
A decrease in osteoprotegerin production may result from